Crinetics Pharmaceuticals, Inc. (CRNX) Q4 2018 Earnings Results

Crinetics Pharmaceuticals Misses on EPS, Stock Up 4.34%

Despite a loss in EPS, Crinetics Pharmaceuticals saw a positive stock reaction, rising 4.34%. This increase may reflect investor optimism about the company's drug development efforts. The lack of revenue figures and guidance leaves some uncertainty, but management's focus on their pipeline could be encouraging for future growth.

The print

Key numbers

Actual vs. consensus

Metric	Actual	Expected	Surprise
EPS	$-0.35	N/A	N/A
Revenue	N/A	N/A	N/A

Management

Management commentary

Tone: Cautiously Optimistic

Management remains focused on advancing their drug candidates. They acknowledged the challenges but emphasized their commitment to innovation.

Management highlighted ongoing efforts in drug development.

They expressed confidence in the pipeline despite the EPS loss.

Crinetics Pharmaceuticals Misses on EPS, Stock Up 4.34%

Key numbers

Management commentary

Crinetics Pharmaceuticals, Inc.

More earnings this week

Crinetics Pharmaceuticals Misses on EPS, Stock Up 4.34%

Key numbers

Management commentary